Loqtorzi®

Understanding Loqtorzi® 

Loqtorzi® (toripalimab-tpzi) is an FDA-approved monoclonal antibody therapy designed to treat specific forms of nasopharyngeal carcinoma (NPC), a cancer that originates in the nasopharynx—the area where the back of the nose meets the upper throat. By targeting specific immune checkpoints, Loqtorzi® helps the immune system recognize and fight cancer cells more effectively.

How Loqtorzi® Works:

• Targets the PD-1 immune checkpoint, allowing T cells to attack cancer cells
• Enhances the immune response against NPC tumors
• Provides an immunotherapy option for patients with advanced or recurrent NPC

FDA Approval:

• Loqtorzi® (toripalimab-tpzi): Approved on October 27, 2023, for the treatment of nasopharyngeal carcinoma (NPC)

For more information, please visit the Loqtorzi® patient website and speak with your healthcare provider to determine if Loqtorzi® is the right treatment option for you.